Pelthos Therapeutics Inc. PTHS
Biotechnology: Biological Products (No Diagnostic Substances) · IPO 2024 · data as of November 13, 2026
Pelthos Therapeutics Inc. (PTHS) is a healthcare company listed in the US with a market value of about $29M. In the twelve months to September 30, 2026 it had revenue of $51M and net income of -$78M, a net margin of -152.2%.
Its overall Stock Analiz score is 0.0 out of 5 (weak). The strongest part is value (0/5); the weakest is value (0/5).
Key numbers: a 5-year average ROIC of -38%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 33% below the current price.
About Pelthos Therapeutics
Pelthos Therapeutics is listed in the US and classified in biotechnology: biological products (no diagnostic substances), IPO year 2024. It was profitable in 0 of the last 4 years in our data. Its share count rose by 4220% over three years (dilution for shareholders). It spends 7% of revenue on research and development.
Score: 0.0 / 5
Checks passed
- —
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
Valuation
Growth and quality
Financials, last 4 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | $51M | $17M | $0 | — | — |
| Net income | -$78M | -$43M | -$8M | -$7M | -$2M |
| Free cash flow | -$33M | -$23M | -$6M | — | — |
| EPS (diluted) | $-23.90 | $-11.52 | $-7.13 | $-28.90 | $28.25 |
| Net margin | -152.2% | -257.9% | — | — | — |
| ROIC | — | -37.6% | — | — | — |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 7 analysts is $41.43, 457% above the current price; targets range from $21.00 to $60.00; the consensus rating is “Strong buy”; expected EPS is $-17.60 for the fiscal year ending December 31, 2026.
Frequently asked questions
Is Pelthos Therapeutics stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 33% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does Pelthos Therapeutics pay a dividend?
Not currently.
Is Pelthos Therapeutics a good stock to buy?
We do not give buy or sell advice. Pelthos Therapeutics scores 0.0 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.